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Neospora caninum is a protozoan parasite that causes abortion in cattle around the 20 
world.  Although the clinical signs of disease in both dogs and cattle have now been 21 
recognised for over 20 years, treatment and control options are still limited, despite the 22 
availability of a commercial vaccine in some countries of the world.  The case for an 23 
efficacious vaccine has not been convincingly waged by farmers, veterinarians and other 24 
members of the agricultural and rural communities.  In recent times, however, economic 25 
modelling has been used to estimate the industry losses due to Neospora-associated 26 
abortion, providing, in turn, the business case for forms of control for this parasite, 27 
including the development of vaccines.  In this review, we document progress in all areas 28 
of the vaccine development pipeline, including live, killed and recombinant forms and the 29 
animal models available for vaccine evaluation.  In addition, we summarise the main 30 
outcomes on the economics of Neospora control and suggest that the current boom in the 31 
global dairy industry increases the specific need for a vaccine against N. caninum-32 
associated abortion. 33 
 34 





1.  Introduction 37 
Neospora caninum, a protozoan parasite closely related to Toxoplasma gondii, is 38 
recognized as a major cause of disease in dogs (Reichel et al., 2007) and, in particular, 39 
abortions in cattle around the world (Dubey et al., 2007).  The parasite impacts seriously 40 
on the economic performance of the dairy and beef industries (Reichel and Ellis, 2006), 41 
with attributable losses measured in the millions of dollars.  Early research efforts were 42 
focussed on the diagnosis of disease (Dubey and Schares, 2006) and the use of diagnostic 43 
tools to obtain a better understanding of the pathology and pathogenesis (Dubey et al., 44 
2006).  It is only more recently that controlling infection and/or abortions have come to 45 
the fore of research into neosporosis (Reichel and Ellis, 2002).  Subsequent reviews on 46 
this topic include those by Brake (2002), Hemphill et al. (2006), Innes and Vermeulen 47 
(2006), Nishikawa et al. (2002) and Williams and Trees (2006). 48 
Treatment options in dogs have recently been reviewed (Reichel et al., 2007).  49 
Essentially, there are a number of drugs available for the treatment of clinically affected 50 
dogs, which may result in the resolution of lesions.  Treatment needs to commence 51 
promptly and be initiated as early as possible before clinical symptoms become 52 
irreversible. 53 
To the primary producer, principally three control options appear available for 54 
dealing with N. caninum in cattle:  a (as yet hypothetical) treatment with a parasiticide 55 
efficacious against N. caninum, a test-and-cull approach where infected animals are 56 
identified and eliminated from the herd (or breeding) and, lastly, vaccination. 57 
Coccidiostatic drugs have been found to be efficacious against some stages of the 58 




al., 2002) and appear to be reasonably efficacious (>90%).  Questions, however, remain 60 
regarding the costs of such treatment and the likely meat and milk with-holding periods. 61 
Test-and-cull approaches have been advocated (Larson et al., 2004) and 62 
successfully implemented in the field (Hall et al., 2005).  Neospora caninum-infected 63 
cows were culled from the herd or not re-bred, and a reduction of the within-herd 64 
prevalence of infection immediately achieved, and preserved, as the rate of new infection 65 
(from post-natal infection) was very low.  Economic analysis suggests, however, that this 66 
approach to controlling neosporosis is also very expensive (Reichel and Ellis, 2006) and 67 
unlikely to be economical, especially if a large part of the herd is infected. 68 
Economic analysis does suggest that vaccination might be the most cost-effective 69 
approach to controlling neosporosis (Reichel and Ellis, 2006), and, largely, preferable to 70 
continuing to live with the disease (Reichel and Ellis, 2008).  An inactivated vaccine 71 
against neosporosis has been available commercially for a number of years, but appears 72 
only partially (~50%) successful in preventing abortions in cattle (Romero et al., 2004).  73 
Live vaccination, utilising tachyzoites of an attenuated strain of N. caninum (NC-Nowra 74 
(Miller et al., 2002)), has demonstrated exceedingly high efficacy (measured as the ability 75 
to prevent abortions due to N. caninum) (Williams et al., 2007), but may suffer as a 76 
commercial product from limited shelf-life and high production cost. 77 
The present manuscript will review the state of current knowledge and likely 78 
future directions of research into a vaccine against N. caninum, with particular emphasis 79 





2.  Neospora caninum 82 
2.1. Life cycle and epidemiology 83 
Neospora caninum infections entail a life cycle between a definitive host (dogs 84 
and some other canids (McAllister et al., 1998)) and the intermediate host (predominantly 85 
cattle, possibly sheep (Dubey et al., 2007)).  Dogs excrete oocysts that become infectious 86 
within a couple of days.  These may infect cattle and lead to either infection with no 87 
discernible clinical symptoms, or induce abortions two to 3 weeks later, usually at about 88 
5-7 months of gestation (Dubey et al., 2006) (Fig. 1).  On the other hand, oral ingestion of 89 
oocysts of N. caninum does not, in itself, reliably lead to infection and/or abortion in 90 
cattle (Trees et al., 2002), suggesting that preventing infection via the faecal-oral route 91 
might not be the critical step in preventing Neospora abortions. 92 
Infected dams that have not aborted may, however, infect their offspring in utero, 93 
a mode of transmission that appears to be highly efficient (~80-95% (Paré et al., 1996; 94 
Davison et al., 1999)) and is thought to cause the majority of infections in the field (Trees 95 
and Williams, 2005).  Abortion may thus be the exception rather than the norm, yet 96 
abortions often involve a large proportion of the cows at risk (i.e. in gestation) and can be 97 
of epidemic proportions (Thornton et al., 1994; Thurmond et al., 1997). 98 
Post-natal transmission has been reported to be of generally low frequency 99 
(around 1% per cow year (Davison et al., 1999; Hietala and Thurmond, 1999)) and thus 100 
appears to only rarely contribute to the perpetuation of infection in the cattle population. 101 
Epidemiological analysis implicates the presence of dogs on farms in abortion 102 




become infected by sporulated oocysts.  Other scenarios suggest that a recrudescence of 104 
the parasite in already, chronically, infected dams leads to abortion (Wouda et al., 1999a). 105 
2.2. Immunity and N. caninum infection 106 
Neosporosis in cattle is predominantly a disease of the pregnant dam that results 107 
in either abortion or vertical transmission of the parasite to the foetus.  Both humoral 108 
(antibody) and cell-mediated immune (CMI) responses have been observed in 109 
experimentally and naturally infected animals (Andrianarivo et al., 2005).  Strong 110 
antibody responses are produced by natural infection, vaccination with whole inactivated 111 
tachyzoites of N. caninum (including the commercially available vaccine) (Andrianarivo 112 
et al., 2005) or lysates of N. caninum tachyzoites in cattle (Williams et al., 2007) and in 113 
the murine model (Miller et al., 2005).  There is doubt, however, that the antibody-114 
responses are protective against abortion or vertical transmission (Innes et al., 2002).  It 115 
has been argued that it is the modulation of the CMI response as part of the naturally 116 
occurring immune-modulatory changes during pregnancy that are at the core of the 117 
abortions often associated with N. caninum infections (Quinn et al., 2002a). 118 
A Th1-type immune response (with, for example, strong IFN-γ and IL-12 119 
responses (Williams et al., 2007; Rosbottom et al., 2008)) is usually induced by N. 120 
caninum infections, but this may interfere with the successful maintenance of pregnancy 121 
and lead to abortion if the infection occurs early in pregnancy (Williams et al., 2000).  In 122 
the later phases of gestation the success of pregnancy relies on a switch to a Th2-type 123 
immune response at the maternal-foetal interface (in order to allow the dam’s immune 124 




parasite and facilitate its transmission across the placenta to the foetus (Innes et al., 126 
2005). 127 
The foetus’ own stage of developing immune-competence will then influence the 128 
outcome; with early gestation infection leading invariably to abortion, and infections later 129 
in pregnancy encountering an increasingly immune-competent foetus that can effectively 130 
contain the N. caninum invasion resulting in congenitally infected, yet clinically normal, 131 
calves being born (Williams et al., 2000). 132 
Because of the peculiarities of its life cycle, a number of questions arise regarding 133 
the epidemiological and immunological events that drive infection and determine 134 
outcomes, i.e. abortion versus congenital infection. 135 
Epidemiological information suggests that post-natal infection is at the root of 136 
abortion epidemics and that the presence of dogs increases the risk of those epidemics 137 
occurring (Bartels et al., 1999; Schares et al., 2004; Hobson et al., 2005).  The timing of 138 
infection also appears to be critical: experimental (de novo) infection with tachyzoites of 139 
a foetopathic strain of N. caninum leads to abortion after about 3 weeks in pregnant cattle 140 
that were infected on Day 70 of gestation.  Infection on Day 210, however, results in the 141 
birth of clinically normal, yet invariably, congenitally infected calves (Rosbottom et al., 142 
2008). 143 
Field experience suggests that N. caninum abortions occur mostly between 5 – 7 144 
months of gestation (Dubey et al., 2006), and may affect a large proportion (up to 56%) 145 
of the cows at risk (Wouda et al., 1999a). 146 
One of the interesting aspects about N. caninum is its ability to repeatedly cause 147 




reduce in subsequent gestations (Thurmond and Hietala, 1997b).  The parasite is even 149 
more efficiently transmitting congenital infection from generation to generation (Paré et 150 
al., 1996), suggesting that the immunity developing after natural infection is either never 151 
very strong, or is sufficiently down-regulated during gestation to allow a recrudescence of 152 
the parasite (Innes et al., 2002).  While abortions are generally reported from early and 153 
mid-gestation, congenital infection appears to occur later in gestation (from mid-gestation 154 
to the third trimester) (Guy et al., 2001). 155 
Both scenarios (repeat abortions and repeated congenital infection of offspring) 156 
would, arguably, not augur well for the possibility of any successful vaccine 157 
development. 158 
2.3. Implications and requirements for a successful/efficacious N. caninum vaccine 159 
The challenge for an N. caninum vaccine appears to be thus either to be able to 160 
prevent infection of the dam, i.e. a vaccine that may be able to prevent a de novo 161 
infection in a previously naïve animal or, in the case of the already (congenitally or post-162 
natally) infected dam to prevent (or ameliorate) a recrudescence of the parasite.  That 163 
might prevent abortion (storms) from occurring, and/or prevent (possibly) repeated 164 
congenital infection of subsequent generation(s). 165 
If the objective is to prevent abortion storms, then the primary infection of an 166 
early to mid-term in-calf cow needs to be prevented.  Arguably the currently available 167 
vaccine is targeting early to mid-term of gestation, with vaccination regimes suggesting 168 
application before breeding commences, or early in the first trimester 169 




focussing on preventing infection from the ingestion of the sporulated, infective oocyst 171 
stage excreted by the dog. 172 
If, however, one assumes that abortions are triggered by a recrudescence of a 173 
latent N. caninum infection, then the transformation of bradyzoites into the fast-174 
replicating tachyzoite stage needs to be curtailed.  That alternative vaccine approach 175 
could be aimed at preventing abortion by enhancing both humoral and cell-mediated 176 
immune responses sufficiently to prevent the recrudescence of an N. caninum 177 
parasitaemia late in gestation in an already infected animal.  This latter approach may 178 
also be successful in preventing (recurrent) congenital infection. 179 
In the face of all these scenarios, what form should a vaccine to prevent N. 180 
caninum infection and/or abortion in cattle take?  There is substantial evidence to suggest 181 
that vaccines can be developed to protozoan parasites that prevent clinical disease, rather 182 
than vaccines that prevent infection, which is a more daunting task. 183 
 184 
3. 3.  Existing (protozoal) parasite vaccines 185 
A number of parasite vaccines are now commercially available, and of particular 186 
interest is the fact that many of these are against protozoa closely related to N. caninum.  187 
Most of them are live vaccines; the first described was a Besnoitia vaccine, a live 188 
attenuated vaccine for cattle based on a naturally occurring isolate from a wildebeest 189 
(Bigalke et al., 1974).  In the case of T. gondii, a commercial vaccine for sheep utilises a 190 
strain of the parasite (S-48) that had lost its ability to form cysts after long-term passage 191 
in mice (Buxton, 1993).  A live cattle vaccine for Babesia bigemina and Babesia bovis 192 




et al., 2004).  Live attenuated vaccines for poultry coccidiosis are also distributed 194 
commercially (Shirley et al., 2005).  However, these (live) vaccines all suffer from 195 
several disadvantages; there is the risk of contamination with other animal pathogens 196 
(Bovine Viral Diarrhoea, Enzootic Bovine Leukosis, to name but a few), the higher cost 197 
of production (as they are usually prepared in cell culture or even in live animals) and a 198 
limited shelf-life with associated stability issues.  For that latter reason, these types of 199 
vaccines are generally only produced to order, limiting their more general appeal and 200 
distribution. 201 
Inactivated vaccines based on whole parasites or modified fractions exist for 202 
Giardia in dogs (GiardiaVax®) (Olson et al., 2000), Sarcocystis neurona (the cause of 203 
Equine protozoal myeloencephalitis) in horses (Marsh et al., 2004) and Leishmania 204 
donovani in dogs (Leishmune®) (Borja-Cabrera et al., 2002, 2004). 205 
Wide-scale attempts to develop vaccines based on individual or combinations of 206 
proteins, including those expressed from a vector system, have not met with great 207 
success.  Within the world of protozoology, arguably the most successful one is a subunit 208 
vaccine, based on native gametocyte antigens, that was introduced to the commercial 209 
world for the control of Eimeria in poultry (Wallach, 1997).  This vaccine has now been 210 
used in millions of broilers around the world (Wallach et al., 2008).  Its manufacture, 211 
however, is technically demanding requiring the infection of chickens, along with 212 
purification of parasites and proteins.  A recombinant version would greatly improve the 213 
ease of manufacture. 214 
Recombinant vaccines to malaria, despite enormous investment, have failed to 215 




Recent effort has come full circle and live and killed vaccines are now again under 217 
evaluation (Good, 2005).  Progress in the creation of knock-out malarial parasites show 218 
that clinical signs of malaria can be prevented in a mouse model (Ting et al., 2008). 219 
Successful recombinant vaccines have, however, been generated for some 220 
parasites.  A highly efficacious (close to 100%), and in recombinant terms simple, 221 
Escherichia coli-expressed, vaccine against Echinococcus granulosus (Eg95) has been 222 
described for a number of years now (Heath et al., 2003; Lightowlers and Heath, 2004) 223 
yet has found little commercial application.  This vaccine’s approach has since been 224 
expanded to include other cestodes, such as Taenia ovis, Taenia saginata and 225 
Taenia solium (Lightowlers, 2006). 226 
In contrast, “hidden (gut)” antigens of the helminth Haemonchus contortus are 227 
highly efficacious in their native form, yet many attempts at producing recombinant 228 
versions of similar efficacy have failed (Newton and Meeusen, 2003). 229 
Recombinant vaccines against Boophilus microplus target a mid-gut protein and 230 
demonstrate varying efficacies around 50% (Andreotti, 2006).  Bm86 homologues in 231 
other Boophilus species are now also being targeted (Odongo et al., 2007). 232 
Clearly the transition from native to recombinant vaccine is an enormous step, yet 233 
to be achieved reliably in the field of anti-parasite vaccines.  Nevertheless, the success of 234 
these developments potentially heralds the beginning of a new era in vaccine 235 





4.  Economics of control 238 
The magnitude of the economic losses incurred by primary producers around the 239 
world due to Neospora-associated abortion has been estimated to exceed hundreds of 240 
millions of dollars per year (Dubey et al., 2007).  In Australia and New Zealand the 241 
estimates for annual losses due to abortions only are AUD $85 million for the dairy 242 
industry in Australia, $25 million in the beef industry and between NZ $17.8 million and 243 
28.4 million annually to the dairy industry in New Zealand (Reichel, 2000; Reichel and 244 
Ellis, 2006).  In Switzerland the median annual loss to the dairy industry was estimated to 245 
be Euro 9.7 million, which included the cost of abortion, the cost of curtailed milk 246 
production, increased veterinary costs and premature culling (Häsler et al., 2006a). 247 
Losses are incurred by a range of aspects of the infection: abortions are the most 248 
prominent effects of N. caninum infection and can be devastating (and costly) when a 249 
large proportion of the at-risk (i.e. in-calf) cow population in a herd may abort (Thornton 250 
et al., 1994; Pfeiffer et al., 2002).  In dairy cattle, the impact on milk production can add 251 
to these economic losses (Thurmond and Hietala, 1997a; Romero et al., 2005), although 252 
others have failed to record a correlation between infection and reduced production 253 
(Pfeiffer et al., 2002).  Neospora caninum-infected cows are also more likely to be culled 254 
early (Thurmond and Hietala, 1996) and in beef cattle, weight gains and final body 255 
weight were negatively affected in serologically positive individuals, and an increase in 256 
veterinary treatment cost observed (Barling et al., 2000). 257 
Previous economic modelling by the authors suggested that the threshold for 258 




infection ranging between 18% to 21%. Below that threshold of infection it was more 260 
economical for the primary producer to live with the infection and risk of abortions.  261 
Dramatic increases in dairy livestock and dairy products can reduce those thresholds to 262 
between 10.8 to 12.6% (Reichel and Ellis, 2008).  A live vaccination approach, possibly 263 
requiring only one vaccination in a cow’s commercial life-time, will reduce this threshold 264 
even further, to a within-herd prevalence of N. caninum infection below 3%. 265 
4.1. Market need 266 
While there have been a number of previous studies that have quantified the cost 267 
of N. caninum infection, it has only been in the last couple of years that the cost of 268 
control has also been estimated and the two compared (Häsler et al., 2006a, 2006b; 269 
Reichel and Ellis, 2006). 270 
There are several options for controlling neosporosis: one aims at eliminating or 271 
decreasing the risk of N. caninum infection at the farm level and consists of either: 272 
 273 
• identification and elimination of either only the (N. caninum) aborted dams, 274 
selective non-breeding from aborted and/or all sero-positive dams or culling of all 275 
sero-positive cattle from the herd (predicated on the assumption that the major 276 
route of transmission in the herd is vertical) 277 
• treatment of all (or all replacement) N. caninum-infected animals in the herd with 278 
a coccidiostat 279 
 280 
Another approach might aim at preventing infection (and thus post-natal 281 





• increased biosecurity (fences, testing of all incoming stock, restrictions placed on 284 
dogs, such as muzzling), in order to reduce the risk of post-natal (horizontal) 285 
infection, or 286 
• vaccination of all susceptible stock, including both sero-positive and sero-negative 287 
cattle present in a herd. 288 
 289 
These options, when fully costed in an economic model, suggested that in 290 
Australasia vaccination is the preferred control option.  With increasing livestock prices, 291 
intervention is economically preferable over continuing to live with the disease (Reichel 292 
and Ellis, 2008), at the demonstrated national level of sero-prevalence of N. caninum 293 
(Reichel, 1998).  This was even true when the commercially available vaccine 294 
(Neoguard®), which shows only limited efficacy was assumed in the model (Fig. 2).  The 295 
benefits, in terms of the cost-benefit ratio, are even more convincing if a fully efficacious 296 
vaccine could be employed (Reichel and Ellis, 2006). 297 
In the Swiss economic model (Häsler et al., 2006a), treatment of all calves with a 298 
cocciodiostat was the economically preferred outcome.  That option, however, is still 299 
only hypothetically available. 300 
An (efficacious) vaccine for neosporosis thus appears to be economically viable 301 





4.2. Customer expectations and concerns 304 
To the primary producer, the most noticeable and most devastating impact of 305 
N. caninum in the herd are abortions, particularly those of epidemic proportions.  While 306 
major inroads have been made into the accurate diagnosis of these abortions, little has 307 
been offered in terms of practical management strategies in either the face of an outbreak, 308 
as a way of minimising the risk of an outbreak, or the repeat of such an occurrence.  309 
Primary producers would want to see a solution that gives them reasonable guarantees of 310 
solving the issue, preventing a (repeat) abortion outbreak in the future, with a rate of 311 
return that makes that option economically viable. 312 
Treatment with a coccidiostat is only hypothetically available at the present 313 
time, while test-and-cull options are expensive, and only viable if uninfected stock can 314 
reliably be bought to replace the culled, infected ones. 315 
Vaccination with the presently available commercial vaccine (Neoguard®) will 316 
interfere with the serological diagnosis of infection, i.e. vaccinated animals cannot be 317 
distinguished from naturally-infected cattle by serological testing (although molecular 318 
testing might be available, at a price, to test for the presence of the parasite in naturally 319 
infected animals viz absence in Neoguard® vaccinated ones).  At the individual farm 320 
level, this may not present a problem, however if animals are traded, the differentiation of 321 
infection versus vaccination status may become an issue. 322 
Neosporosis, however, is not a notifiable disease in most countries (although it 323 
is in Switzerland (Häsler et al., 2006a)), and thus very few countries would require testing 324 
for N. caninum infection in international trade.  There is thus also no impediment to live 325 




regulatory process) against the possibility of a reversion to virulence, or wider 327 
dissemination of the vaccine parasite population into the wider target population. 328 
Live vaccination may also present a problem with the timely delivery of vaccine 329 
doses, as storage and distribution of such a vaccine will be dependent on the provision of 330 
an efficient cold chain.  In countries or regions with marked seasonal calving patterns this 331 
may put particular strains on production capacities (for example New Zealand, and 332 
Switzerland to an extent).  On a positive note, however, seasonal calving systems may 333 
greatly enhance vaccine uptake because of the potential ease of scheduling vaccine 334 
production prior to need. 335 
 336 
5.  Animal models 337 
Proof of concept for a vaccine requires a pathway of evaluation that ultimately 338 
relies on animal models.  Mouse models, despite their limitations, are a helpful first 339 
screen, however the cow is the target species and it is necessary to carry out vaccination 340 
protocols in that species.  In the case of neosporosis, mouse and cattle models exist 341 
through which vaccine approaches can and have been evaluated.  342 
A number of trials with putative N. caninum vaccine candidates have involved the 343 
use of mice as an initial screen for the potential of the candidates.  Mouse models for both 344 
CNS disease (cerebral neosporosis) and for transplacental transmission, exist and have 345 
been extensively validated (Atkinson et al., 1999; Miller et al., 2002).  A model 346 
mimicking the abortion effect of N. caninum appears to be more difficult to reproduce in 347 
mice (Quinn et al., 2002b), although other researchers have persisted with this approach, 348 




can be identified in pregnant mice infected by N. caninum (Long and Baszler, 1996), and 350 
so determining foetal loss is an attractive method for determining vaccine efficacy in the 351 
mouse (Quinn et al., 2002b). 352 
A model for cerebral (CNS) disease based on the BALB/c mouse is attractive 353 
because of the florid brain pathology (Lindsay et al., 1995a) produced as a result of 354 
inflammation that may also be associated with other clinical signs of disease such as head 355 
tilting, limb paralysis and circling motion (Fig. 3).  Monitoring weight loss over the 30 356 
days p.i. provides a reliable way to monitor the outcome of infection, as a decrease in 357 
body weight by 20% (a humane experimental end point) is normally associated with 358 
subsequent death in this model.   359 
Changes in clinical signs of infection in mice is also the basis of a scoring system 360 
suggested by Bartley and colleagues (Table 1) (Bartley et al., 2006).  Infection of mice by 361 
N. caninum, like strains of T gondii, induces disease that is reflected by the natural 362 
progression of clinical signs such as ruffled coat (Fig. 4), inactivity and weight loss, and 363 
so by scoring the appearance of these, an acceptable end point for the experiment can be 364 
reached (in the absence of death due to disease). 365 
C57BL/6 mice are also recognised as a way to evaluate vaccines (Ramamoorthy 366 
et al., 2007a).  The lethal challenge model described would be unacceptable to most 367 
developed countries of this world, since death is not recognised as a humane end point.  368 
Mice that die from a lethal dose of tachyzoites do so probably from peritonitis and organ 369 
failure.  In contrast, mice given a sub-lethal dose show a range of pathological features 370 
upon which a scoring system and a method for quantization of levels of brain pathology 371 




although assessment of brain pathology even with this scoring system is still a very 373 
subjective measure of infection and the responses to it. 374 
Real-time PCR can also be used to measure parasite burden in tissues (Collantes-375 
Fernandez et al., 2006), and so can be used to monitor quantitative changes amongst 376 
vaccinated and non-vaccinated groups (Vemulapalli et al., 2007).  Real-time PCR 377 
therefore does have a role to play in evaluating vaccine efficacy where there is a need to 378 
determine parasite numbers (such as in mouse experiments, Table 3). 379 
C57BL/6 mice have also been used in studies on transplacental transmission to 380 
evaluate vaccines (Ramamoorthy et al., 2007c).  Since these mice (like the BALB/c) are 381 
susceptible to infection and the dam is likely to experience a life threatening infection, the 382 
interpretation of data on transmission in utero may be difficult.  Under conditions of such 383 
an infection mice typically resorb their foetuses (depending on tachyzoite dose and time 384 
of infection), and so the extent of the data generated may not be sufficiently rigorous for 385 
vaccine studies. The study by Ramamoorthy et al. (2007c) is therefore highly significant 386 
because the vaccination data suggest that susceptible animals can be used in vaccine 387 
trials, since it may provide extra levels of selection for protective immunity (dam 388 
survival, foetal survival (Fig. 5) and transplacental transmission).  In the BALB/c mouse, 389 
mortality is also the main outcome of post-natal development of pups infected with N. 390 
caninum during pregnancy (Lopez-Perez et al., 2008).  391 
We pioneered the use of the Quackenbush (Qs) mouse as a model of 392 
transplacental transmission.  The Qs mouse is a large mouse that is innately resistant to N. 393 
caninum-induced pathology in the adult (Fig. 6).  Infections of N. caninum given during 394 




mention is the large litter sizes associated with this mouse type, with litters up to 15-20 396 
being common.  Consequently quality data on transplacental transmission (Table 4) can 397 
be generated from the number of pups that are infected during vaccine 398 
(immunisation/challenge) evaluation-style experiments (Miller et al., 2005). 399 
Despite all these advances in using mice as a strategic screen for vaccine efficacy, 400 
one ultimately needs to do cattle trials with putative vaccine candidates.  Trials with cattle 401 
are more expensive, and also hampered by the longer gestational period of cattle.  They 402 
present, however, the target species for any commercially successful vaccine and need to 403 
be carried out, if only to satisfy the regulatory processes and to demonstrate efficacy.   404 
A vertical transmission model was initially reported by Innes et al. (2001b) 405 
(challenging cattle in mid-gestation at Day 140), who demonstrated the efficacy of a live 406 
tachyzoite vaccination in preventing congenital transfer to the foetus (Table 5).  Currently 407 
the cattle immunisation/challenge model (Williams et al., 2007) is the most valuable 408 
addition to the repertoire of approaches available for vaccine evaluation.  The limitation 409 
of this approach is clearly the ability of the challenge strain to reproducibly induce foetal 410 
death/abortion.  A number of factors may affect the ability of the selected strain to do 411 
this.  Probably the most important to consider is that long-term passage of N. caninum 412 
may potentially ameliorate parasite virulence, thereby limiting the effectiveness of a 413 
cultured organism to cause clinical disease (Bartley et al., 2006). 414 
The same study (Williams et al., 2007) also demonstrated that live tachyzoite 415 
vaccination can be highly efficacious in preventing abortions (against a challenge at Day 416 
70 of gestation).  While foetuses were protected, the dams also, apparently, did not 417 




This would suggest some promise for a commercial vaccine, as persistence or even 419 
spread of the live vaccine in the target population does not appear to be a concern (as it 420 
might be, from a regulatory point of view, for live vaccines). 421 
Sheep are also highly susceptible to N. caninum infections and have been used as 422 
a model to facilitate the study of Neospora pathology, as well as the effects of 423 
vaccination (Buxton et al., 1998, 2001; Innes et al., 2001a; Jenkins et al., 2004c), as have 424 
pygmy goats (Lindsay et al., 1995b). 425 
 426 
6.  Evaluation of vaccine efficacy in field trials  427 
 Similarly the conduct of field trials using vaccines to N. caninum is equally complex.  428 
Reproductive loss, by its very nature, can result from a variety of causes and a number of 429 
published studies to date have often concentrated on monitoring changes in abortion 430 
levels per se ( Muñoz Bielsa, J., Romero, J.J., Heuer, C., 2004. Control of neosporosis in 431 
cattle with Bovilis® Neoguard: the field experience. In, World Buiatrics Conference, 432 
Quebec; Romero et al., 2004), rather than specifically targeting Neospora-associated 433 
abortion.  On the other hand, N. caninum lesions are quite distinct (Dubey et al., 2006), 434 
and diagnosis of specific Neospora-abortions is potentially feasible and necessary.  435 
Future field trials may be advised to monitor these as a specific measure of a vaccine’s 436 
efficacy. 437 
 438 
7.  Alternative approaches for vaccine development  439 
Within the context of vaccine development, it is worthwhile here to document 440 
current knowledge on potential methods and molecules that may form the basis of a 441 




range of approaches being evaluated, with live vaccination being the most advanced in 443 
development. 444 
7.1.  Inactivated vaccines 445 
Irradiated tachyzoites of N. caninum have been used to protect mice from an 446 
otherwise lethal challenge (Ramamoorthy et al., 2006).  This approach has also been used 447 
successfully in the case of a commercial vaccine, which utilises 1,000 irradiated L3s, 448 
inoculated twice, 4 weeks apart, for the cattle lungworm Dictyocaulus viviparous 449 
(Intervet, Huskvac 450 
http://www.intervet.co.uk/Products_Public/Bovilis_Huskvac/090_Product_Datasheet.asp 451 
). 452 
The only commercially available vaccine against N. caninum (Neoguard®, 453 
Intervet) contains 3 x 106 inactivated tachyzoites (and Havlogen as the adjuvant) and is 454 
applied prior to breeding or early in the first trimester of gestation twice (formulated in a 455 
5 mL dose), 4 weeks apart, with one or two annual booster vaccinations.  The induced 456 
immunological response appears to be mainly humoral in nature (Andrianarivo et al., 457 
2000).  It has however been demonstrated that cell-mediated responses are instrumental 458 
in effective protection against infection/abortion (Innes et al., 2002; Williams and Trees, 459 
2006). 460 
 461 
7.2.  Live vaccines 462 
A commercial vaccine available for T. gondii (Ovilis Toxovax®, Intervet) uses the 463 




the sheep (Buxton, 1993).  This prevents a persistent infection and subsequent 465 
recrudescence, as appears to be sometimes possible with field infections (Buxton et al., 466 
2007).  The development of this vaccine is, however, important in that it shows that a 467 
vaccine can be produced that prevents abortion due to a parasitic infection of a livestock 468 
animal.  In addition, it shows admirably that manufacturing and distribution issues 469 
surrounding the sale of a live vaccine are surmountable, when there is a market driving 470 
such a vaccine.  Toxovax® is distributed in New Zealand, for example, where millions of 471 
doses/year are regularly sold. 472 
Live vaccines for N. caninum can take on many forms, but are likely to be based 473 
on populations of parasites that are attenuated in one or more of their phenotype 474 
characteristics.  Temperature –sensitive mutants and irradiated tachyzoites represent two 475 
such populations which have been reported (Lindsay et al., 1999; Teixeira et al., 2005; 476 
Ramamoorthy et al., 2006).  Both types are successful at inducing immunity in a mouse 477 
that reduces or completely prevents the onset of clinical signs of disease, as well as brain 478 
pathology associated with infection.  There are no reports yet of trialling these attenuated 479 
parasites in pregnant cattle. 480 
Naturally attenuated wild-type populations of N. caninum are currently under 481 
evaluation as live vaccines and progress has been rapid.  Specifically, a live vaccine 482 
approach that prevents abortion in cattle, based on tachzyoites isolated from naturally 483 
infected animals that do not show signs of neosporosis, is currently being explored.  The 484 
extensive observations that N. caninum can exist in cattle without them showing any 485 
clinical signs of disease may represent the ease through which this parasite can adapt to 486 




abortion and typically carry their calves to term, leading to the birth of a normal calf 488 
(Barr et al., 1993).  Whether this really represents adaptation of the parasite to its host or 489 
other scenarios such as induction of immunity is really not known.  However it is clear 490 
that tachyzoites derived from asymptomatic calves may be attenuated in their ability to 491 
cause disease in the mouse and therefore represent leads for a cattle vaccine.  Several 492 
lines of evidence show this to be true. 493 
NC-Nowra was first isolated from a calf without any clinical signs of infection, 494 
and it was identified through a comparison with NC-Liverpool as attenuated in its ability 495 
to induce clinical signs of disease and brain pathology in mice (Miller et al., 2002).  496 
Vaccine trials in mice (Miller et al., 2005) showed that infection of mice with NC-Nowra 497 
before pregnancy resulted in a dramatic reduction in transplacental transmission of a 498 
challenge strain given during pregnancy.  Miller et al. (2005) used live tachyzoites of 499 
NC-Nowra to vaccinate outbred Qs mice before pregnancy and this reduced vertical 500 
transmission by more than 80-90%. The application of multiplex PCR confirmed the 501 
identity of the N. caninum in the remaining infected pups as the challenge strain NC-502 
Liverpool (Al-Qassab et al., 2009).  Subsequent inoculation of 107 tachyzoites of NC-503 
Nowra into cattle prior to breeding protected 100% of foetuses from death by an 504 
otherwise lethal challenge by NC-Liverpool at Day 70 of gestation (Williams et al., 505 
2007).  In the same study lysates of NC-Nowra also failed to protect cattle from abortion 506 
(Williams et al., 2007).  Such data clearly calls for further evaluation of the live vaccine 507 
approach, although this strategy may warrant concerns regarding the possibility of the 508 
inoculum persisting in the host.  In the study by Williams et al. (2007) the inoculated 509 




another concern undermining the live vaccine approach, but as yet there are no reports of 511 
this occurring from animal experiments.  Finally, another concern may be whether N. 512 
caninum is responsible for early foetal loss in cattle.  In mice, prior infection with N. 513 
caninum was reported to reduce the number of pups/litter, and field work with cattle 514 
provided anecdotal evidence for early foetal loss (in that sero-positive cattle required 515 
more attempts by artificial insemination that sero-negative cows to generate a pregnancy) 516 
(Hall et al., 2005). 517 
Other isolates are now starting to emerge with biological properties that, like NC-518 
Nowra, are attenuated in their ability to cause disease in mice.  Nine isolates were made 519 
from asymptomatic calves in Spain (Regidor-Cerrillo et al., 2008), and one of them (Nc-520 
Spain-1H) failed to induce clinical signs in a BALB/c mouse, grew slowly in vitro, and 521 
provided protection against foetal death in a pregnant mouse model (Rojo-Montejo et al., 522 
2009).  Isolates from Spain, a country where bovine spongiform encephalopathy in cattle 523 
is increasing in incidence, are unlikely to find global appeal for live vaccine development, 524 
especially for big dairy markets such as the USA, where safety concerns for food-borne 525 
diseases are high on the agenda. 526 
The potential short shelf-life of a live vaccine product means that the manufacture 527 
and distribution of the live vaccine to meet the potentially large global market that exists 528 
in cattle producing countries requires further consideration.  Experience with Toxovax® 529 
shows, however, that these potential problems with the distribution of a live formulation 530 
can be overcome. 531 
The manufacture of a live vaccine also requires that several issues relating to the 532 




tissue culture and the viability of tachyzoites can be easily assessed by in-vitro culture.  534 
The growth of tachyzoites can be observed simply through changes in cell number (Lei et 535 
al., 2005b).  PCR also allows the monitoring of tachyzoite viability (Strohbusch et al., 536 
2008).  While thus far used for the evaluation of the efficacy of compounds for the 537 
treatment of N. caninum tachyzoites, such PCR approaches may also be of value in the 538 
future for the quality control of tachyzoite numbers in commercial production of any live 539 
vaccine. 540 
7.3. Subunit (and recombinant) vaccines 541 
 Most studies published to date have focussed on the evaluation of tachyzoite 542 
proteins for their vaccine potential despite the fact that it is still not clear whether this life 543 
cycle stage contains protective antigens.  That tachyzoites contain molecules that confer 544 
protective immunity is debateable, since lysates derived from them have shown varying 545 
ability to induce immunity.  For example, Liddell et al. (1999a) showed that a single 546 
injection of a crude lysate into mice before pregnancy completely prevented vertical 547 
transmission in BALB/c mice (Liddell et al., 1999a).  In contrast, Miller et al. (2005) 548 
showed that an immune response generated to a lysate from NC-Nowra did not prevent 549 
transplacental transmission of a challenge strain given during early gestation (Miller et 550 
al., 2005).  Unfortunately, no comparison has yet been made between the vaccination 551 
outcomes using lysates made from different isolates, but such a comparison may be 552 
helpful in overcoming the doubt that exists on lysates as a vaccine.  Proteomic analyses 553 
have shown that tachyzoites from two different isolates of N. caninum are not identical in 554 
their molecular composition, suggesting that natural variation exists amongst natural 555 




the ability of a tachyzoite preparation to act as an effective vaccine is unknown; 557 
nevertheless, the study by Liddell et al. (1999a) gave hope that a subunit vaccine was 558 
potentially feasible (Liddell et al., 1999a). 559 
 The molecules present in the Excreted Secreted (ES) fraction are now being more 560 
thoroughly defined (Jenkins et al., 2004b; Liao et al., 2006).  This fraction, although 561 
difficult to produce in terms of quantity and quality, contains many of the molecules that 562 
are now recognised as important antigens of N. caninum (some of which are described 563 
below).  In its own right, this fraction may be worth evaluating in a cell-free vaccine 564 
formulation. 565 
 Generic approaches for the discovery, identification and subsequent 566 
characterisation of vaccine candidates from N. caninum have previously been 567 
documented (Hemphill et al., 1999; Jenkins, 2001; Ellis et al., 2003).  A large number of 568 
proteins are known to exist in N. caninum (Lee et al., 2003, 2004) and, similar to current 569 
research on other Apicomplexa, the choice of candidates for vaccine evaluation has 570 
focussed on those that are likely to be located on the parasite surface (such as membrane 571 
proteins) or involved in parasite-host interaction.  In the case of the latter, those 572 
molecules present and secreted from organelles such as micronemes and dense granules 573 
during host cell invasion are a common choice (Mercier et al., 2005).  Such molecules are 574 
also typically found in the ES fraction that can be produced from parasites maintained in 575 
vitro.  Many such molecules, identified initially because of their antigenic properties, 576 
have now been characterised from N. caninum. 577 
From first principles it appears irrational to suggest that molecules found in N. 578 




coccidian, are good vaccine candidates.  Vast differences exist in the biology of these 580 
species, which suggests that a common mechanism of immunity is unlikely.  Indeed a 581 
model of common (e.g. the importance of IFN-γ as a central defence mechanism) and 582 
species-specific host responses (eg antibody production) is obviously applicable to the 583 
Toxoplasmatinae.  For example, infections by T. gondii and N. caninum do not induce 584 
cross-protective immunity (Lindsay et al., 1990; Innes et al., 2001a).  However, extensive 585 
studies on the composition of the Toxoplasmatinae (and Apicomplexa more generally) 586 
show that a wide variety of taxa share many molecules.  Consequently, it is difficult to 587 
ignore the vast amount of vaccine-related research that has occurred in malaria and other 588 
Apicomplexa, where proteins that are homologous amongst species are easily identifiable 589 
(Wan et al., 1996; Ajioka, 1998; Ajioka et al., 1998; Ellis et al., 2003; Li et al., 2003).  590 
This research may clearly provide useful pointers to those molecules that may determine 591 
or direct the host-parasite relationship that can be the focus of vaccine development.  592 
The ability of proteins to interact and direct the host immune response (antigenic 593 
in the broadest sense) represent one criterion by which N. caninum molecules can be 594 
selected for evaluation as vaccines.  Those molecules that are antigens have now been 595 
extensively studied, and indeed detection of antibody to such molecules was one of the 596 
first approaches to define the immunodominant molecules of N. caninum (Hemphill and 597 
Gottstein, 1996; Lally et al., 1996).  More recently, proteomic approaches were used to 598 
define more broadly the immune-dominant molecules present in tachyzoites of N. 599 





One useful approach that has emerged for the rapid assessment of a molecule’s 602 
vaccine potential is the evaluation of antibodies raised against the molecules to prevent in 603 
vitro attachment and invasion.  Several studies have shown that antibodies raised to 604 
recombinant proteins can reduce cell invasion in vitro, suggesting that induction of 605 
antibodies in vivo by vaccination is worth further evaluation (Augustine et al., 1999; 606 
Zhang et al., 2007b; Debache et al., 2008). 607 
Cyclophilin, first identified in N. caninum as an expressed sequence tag (Hemphill 608 
and Gottstein, 2000), is a fine example where common knowledge from the T. gondii 609 
discipline has helped shape research into N. caninum.  In T. gondii, cyclophilin is an 18 610 
kDa protein that is a potent stimulator of IFN-γ (Aliberti et al., 2003; Golding et al., 2003; 611 
Yarovinsky et al., 2004).  Since IFN-γ is a central mediator of immunity to N. caninum 612 
and other parasitic protozoa (Innes et al., 1995; Quinn et al., 2002a), such molecules that 613 
stimulate production of this important cytokine must rank high on the list of vaccine 614 
candidates for evaluation.  615 
 Molecular function and cell location are other important criteria to consider during 616 
vaccine development.  The literature in parasitology is full of references to molecules that 617 
have important roles in cell structure, metabolism, respiration, as well as many other 618 
cellular activities.  Should one focus on identifying essential functions as targets for 619 
vaccine development?  Clearly there is some evidence that this approach may be an 620 
effective strategy since targeting of hidden antigens would appear to be a worthwhile aim 621 
in protozoology (Knox, 2000; Nuttall et al., 2006).  Molecular function is also closely 622 




 As with T. gondii, the surface of the N. caninum tachyzoite is dominated by the 624 
glycosylphosphatidylinositol (GPI) anchored protein SAG1 homologue (Lei et al., 625 
2005a), also known as p29 (Howe et al., 1998).  Although other molecules are present 626 
and detectable in membrane preparations by Western blotting, the relative abundance of 627 
these is significantly lower (Lei et al., 2005a).  Previously we reported the presence of a 628 
22 kDa protein on the surface of N. caninum tachyzoites (Lei et al., 2005a), but 629 
subsequent protein analyses showed this was not an N. caninum protein and so was not 630 
pursued further (unpublished data).  Immunisation of mice with recombinant SAG1 631 
shows significant protection against cerebral infection by N. caninum (Cannas et al., 632 
2003a). 633 
 The surface of the T. gondii tachyzoite also contains members of a family of SAG 634 
related sequences (SRS) (Jung et al., 2004).  A homologue of the SRS2 surface protein of 635 
T. gondii is known to be present on the surface of N. caninum (Hemphill and Gottstein, 636 
1996; Hemphill et al., 1997; Howe et al., 1998) and is found on both tachyzoites and 637 
bradyzoites (Hemphill, 1996; Fuchs et al., 1998).  Antibodies raised to SRS2 can partially 638 
inhibit tachyzoite attachment and invasion of host cells (Hemphill, 1996; Nishikawa et 639 
al., 2000c; Cho et al., 2005; Haldorson et al., 2006).  Recent evidence suggests this 640 
molecule is also a strong vaccine candidate.  Mice immunised with iscoms containing 641 
recombinant SRS2 had lower amounts of N. caninum DNA in their brains compared to a 642 
control group (Pinitkiatisakul et al., 2005, 2007) and improved gerbil survival (Cho et al., 643 
2005).  Another study demonstrated that inoculation of native SRS2 into mice induced 644 
immunity that prevented transplacental transmission in mice (Haldorson et al., 2005).  645 




may be insufficient to prevent transplacental transmission of N. caninum.  NcSRS2 647 
coupled to palmitic acid (giving a lipoprotein), when injected into cattle with Freund’s 648 
adjuvants, induced T-cell activation and IFN-γ secretion, similar to that induced by a live 649 
N. caninum infection (Staska et al., 2005; Baszler et al., 2008).  Such observations 650 
suggest that vaccine trials with SRS2 in cattle are warranted. 651 
 Dense granules (DG) are secretory organelles found in cyst-forming coccidia.  The 652 
contents of DG are typically secreted into the parasitophorous vacuole (PV) during the 653 
invasion process, and appear important for the establishment and functioning of the 654 
vacuole.  NCDG1 was the first DG antigen reported from N. caninum and is 43% 655 
identical to TgGRA7 (Lally et al., 1997).  Subsequently NCDG2, similar to TgGRA6, 656 
was identified (Liddell et al., 1998).  Both of these proteins are immunogenic in cattle 657 
since they were subsequently used to demonstrate antibody responses in cattle (Lally et 658 
al., 1996).  Other well characterised DG proteins are nucleoside triphosphate hydrolase 659 
(NTPase) (Asai et al., 1998) and GRA2 (Ellis et al., 2000), the later which is 50% similar 660 
to TgGRA2.  NCGRA7 was recently identified as the 17 kDa immune-dominant antigen 661 
of tachyzoites (Alvarez-Garcia et al., 2007).  Previous DNA vaccination studies showed 662 
prevention of foetal infection when dams were immunized with NcGRA7 (plus CPG) 663 
(Liddell et al., 2003; Jenkins et al., 2004a).  Dense granules also produce novel protease 664 
inhibitors that are discharged during infection into the PV (Morris et al., 2004). 665 
 Other subcellular organelles are the micronemes and rhoptries.  Evidence suggests 666 
that injection of NcMIC1 or NcMIC3 into mice prevents a subsequent cerebral infection 667 
by an N. caninum challenge (Cannas et al., 2003b; Alaeddine et al., 2005).  NcMIC10, a 668 




proved of no value in vaccination studies using mice (Ellis et al., 2008).  An E. coli 670 
expressed rhoptry antigen (Debache et al., 2008) confers protection in mice in the 671 
cerebral disease model (preventing development of clinical signs completely and reduced 672 
parasite loads significantly) (Debache et al., 2008).  In vitro studies with antibodies to 673 
NcROP2 also demonstrated that these prevented host cell invasion. 674 
 Apical membrane protein 1 (AMA-1) is one of the lead vaccine candidates in 675 
malaria (Remarque et al., 2008).  It is a merozoite protein that plays a role in the early 676 
invasion process.  AMA-1 appears on the surface of merozoites after release from 677 
rhoptries and subsequent processing events.  The extent of the vaccine related work on 678 
AMA1 in malaria is worthy of mentioning here, since these studies have progressed from 679 
laboratory-based studies to proof-of-concept for a vaccine in the field.  The discovery 680 
pathway is therefore of historical interest.  Initially it was observed that monoclonal 681 
antibodies to the Plasmodium knowlesi protein prevented merozoites from invading 682 
erythrocytes (Deans et al., 1982).  Immunisation with native AMA-1 protected rhesus 683 
monkeys against homologous challenge (Deans et al., 1988).  Subsequent studies 684 
demonstrated mice immunised with AMA-1 from Plasmodium chabaudi displayed high 685 
levels of protection (Crewther et al., 1996; Anders et al., 1998).  Only a low degree of 686 
similarity exists between AMA-1 of Plasmodium species and TgAMA-1 of T. gondii 687 
(Hehl et al., 2000), however 12 of the 16 cysteines that are invariant in Plasmodium are 688 
conserved in TgAMA-1, suggesting that folding of the protein is conserved.  In the cyst-689 
forming coccidia this molecule is produced during tachyzoite replication and is located in 690 
the micronemes.  TgAMA1 is predicted to be a type-1 transmembrane protein that is 691 




which is released from the parasite and a 12 kDa C-terminal fragment that remains 693 
associated with the tachyzoite (Donahue et al., 2000).  Mouse antiserum to TgAMA-1 694 
blocked tachyzoite invasion of host cells by approx 40% (Hehl et al., 2000).  NcAMA-1 695 
shows 73% identity to TgAMA-1 (Zhang et al., 2007a) and a 57 kDa product is released 696 
into the excreted secreted fraction of N. caninum.  Antibodies to NcAMA-1 inhibited host 697 
cell invasion by 67%.  AMA1 may therefore warrant further evaluation as a vaccine 698 
candidate. 699 
 Many of the N. caninum proteins summarised in Tables 3 and 4 were produced in 700 
either bacterial or eukaryotic expression systems and either recombinant DNA or purified 701 
protein evaluated as vaccines in mice.  It is unfortunate that native protein was not used in 702 
most of the trials, since there are numerous issues associated with using recombinant 703 
protein (see Section 3 for example) that may prevent a molecule truly acting as a vaccine.  704 
As mentioned above, native SRS2 showed promise as a vaccine (Haldorson et al., 2005). 705 
7.4. Vector vaccines  706 
Vaccinia virus has been used to deliver NcSRS2 to mice (Nishikawa et al., 2000b).  707 
The choice of this vector system was based on the arguments that it had a wide host range 708 
(and so can be used in cattle) and the capacity to induce both humoral and cellular 709 
immunity.  The available evidence from vaccination using recombinant vaccinia 710 
expressing SRS2 shows that an IgG1 antibody was produced in response to vaccination 711 
as well as IFN-γ (Nishikawa et al., 2001a, 2001b).  Vaccination with these vaccinia 712 
constructs was able to reduce the load of N. caninum in the brains of mice (Nishikawa et 713 
al., 2001a) as well as the transplacental transmission of N. caninum in utero (Nishikawa 714 




delivery of virus intranasally to dogs resulted in the induction of antibody that detected N. 716 
caninum antigen by Western blotting (Nishikawa et al., 2000a). 717 
Others have used Brucella abortus with success as a delivery system for a number of 718 
N. caninum antigens, namely MIC1, MIC3, GRA2, GRA6 and SRS2 (Ramamoorthy et 719 
al., 2007b, 2007c).  MIC 1 and GRA 6 conferred complete protection from lethal 720 
infection.  However, while promising, the use of B. abortus as a vector might not be 721 
acceptable in the cattle populations of countries that want also to demonstrate freedom 722 
from bovine brucellosis.  In passing we note that the RB51 strain used in the above-723 
mentioned studies does allow the differentiation of vaccinated versus cattle naturally 724 
infected with B. abortus via appropriate testing.  It therefore appears a potentially 725 
valuable system with which to investigate the vaccine potential of N. caninum molecules. 726 
 727 
8.  Discussion 728 
The development of vaccines to Neospora-associated abortion in cattle represents 729 
an interesting proposition to consider.  It is tempting to hypothesise, as suggested by 730 
others (Innes et al., 2002; Williams and Trees, 2006), that prevention of infection in cattle 731 
ultimately will be the main strategy to prevent abortion.  However there is no evidence 732 
that natural sterilising immunity occurs in cattle to N. caninum, leading to cattle free of 733 
infection.   In contrast, the development of an anti-disease vaccine that prevents abortion 734 
appears achievable.  The demonstration that infection of cattle prior to pregnancy with N. 735 
caninum induces immunity that prevents subsequent foetal death is an important advance 736 




The development of anti-disease vaccines have been previously highlighted by the 738 
advances in malaria (Schofield, 2007) where malarial GPI anchors play a major role in 739 
the induction of pathology and pro-inflammatory responses via a mechanism involving 740 
TNF production.  Glycosylphosphatidylinositols have been reported from N. caninum 741 
(Schares et al., 2000) but it is unknown whether they contribute to the pathologic process 742 
occurring during infection.  Recent studies on the placenta of cattle have shown a 743 
correlation of placental pathology (Maley et al., 2006; Gibney et al., 2008) and cytokine 744 
responses (Rosbottom et al., 2008) with foetal loss, and so it may be reasonable to focus 745 
on the characterisation of N. caninum molecules that are associated with the induction of 746 
these pathologic processes.  747 
The mouse model for cerebral neosporosis (Atkinson et al., 1999; Bartley et al., 748 
2008) has been used extensively for evaluation of vaccine candidates.  There are several 749 
generalisations that can be made from consideration of such studies (summarised in 750 
Tables 3 and 4).  Induction of non-specific immunity by, for example, the adjuvant used 751 
in the trials (e.g. RIBI (Alaeddine et al., 2005) or the vector RB51 (Ramamoorthy et al., 752 
2007b)) can prevent induction of clinical signs of disease, typically associated with 753 
neosporosis in a mouse.  In some cases, this makes assessment of protection very 754 
subjective in the way the levels of protection are calculated.  Mouse survival and 755 
prevention of weight loss can also occur in the presence of variable numbers of parasites 756 
(as judged by PCR) or pathology detectable in the brain.  Immunohistochemistry is a poor 757 
indicator of protection as parasites are rarely seen in sections (Cannas et al., 2003a, 758 
2003b; Alaeddine et al., 2005).  The method of measuring protection in the cerebral 759 




study (Vemulapalli et al., 2007) protection was measured by the number of animals not 761 
returning a positive PCR result, or by comparing mean results from the group.  Quite 762 
different levels of protection can be calculated depending on the criterion used.  The 763 
vertical transmission model is less subject to interpretation, although PCR sensitivity is 764 
an obvious limitation in the comparison of data from different labs. 765 
The development of new animal models for investigating vaccines is also needed.  766 
Some types of mice tested do not show satisfactory levels of foetal loss, and thus are 767 
limiting in their capacity as predictive systems for the development of a vaccine against 768 
bovine abortions.  Implantation analysis in mice (based on foetal viability) is relatively 769 
simple to conduct and is an attractive approach to adopt.  The use of sheep or other 770 
ruminants in trials, when cattle are the main target species, would appear to have limited 771 
value. 772 
Live vaccination is currently the most advanced technology available for the 773 
control of abortion in cattle due to N. caninum, with the greatest chance of success, if 774 
efficacy (100% or close to it) is considered as a measure of commercial and economic 775 
success.  The evidence to date shows that vaccination with a naturally-attenuated strain of 776 
N. caninum (such as NC-Nowra) can prevent foetal death.  It also did not persist to any 777 
detectable level in the vaccinated dam; nor did it pass via congenital transmission to the 778 
surviving foetus (Williams et al., 2007).  This advance can be regarded as the Mark I 779 
prototype version of an efficacious Neospora vaccine.  There are of course a number of 780 
remaining issues to address during further development of this vaccine; safety is a 781 
paramount concern, although prescribing such a vaccine for use in the non-pregnant 782 




also needs to be further investigated as well as dissemination of the strain to native fauna.  784 
The information available to date, however, indicates that NC-Nowra does not persist or 785 
transmit to subsequent generations (Williams et al., 2007).  NC-Nowra also derives from 786 
a calf born in a country (Australia) recognised to be free of BSE.  Neospora caninum, 787 
unlike T. gondii, is not recognised as a human pathogen and evidence to date shows that 788 
N. caninum is rarely detected by serology in the human population (Petersen et al., 1999; 789 
Tranas et al., 1999), hence spread to the human population (possibly through meat 790 
consumption) may not be a concern.  In addition, the short shelf-life of live vaccines such 791 
as Toxovax® shows the need for advances in technology behind cell storage and survival.  792 
A live vaccine based on an attenuated strain of N. caninum, such as NC-Nowra, could be 793 
registered quickly, over a period of four to 5 years and brought to the market. 794 
There is still wide scope for evaluation of killed formulations of N. caninum as 795 
vaccines, potentially limited only by the availability of acceptable adjuvants.  Although 796 
the immunodominant antigens of tachyzoites are at an advanced stage of definition and 797 
characterisation, those from other life cycle stages, such as bradyzoites (Fernandez-798 
Garcia et al., 2006; Risco-Castillo et al., 2007), are not.  Similarly, it is not clear whether 799 
they are involved in the generation of immunity and the role they may play in this 800 
process.  Recombinant antigens have been produced in both prokaryotic and eukaryotic 801 
expression systems (Cannas et al., 2003a, 2003b; Ellis et al., 2008), however T. gondii 802 
may well be the best system to explore for production of N. caninum protein.  803 
Genetic manipulation of T. gondii is feasible and available technology could 804 
easily lead to the development of a novel class of live vaccines where N. caninum 805 




manipulated organisms, however, probably limits this approach to one of scientific 807 
curiosity, although one can imagine a plethora of novel methods for identification of 808 
potential vaccine targets. 809 
Rapid advances are also being made in “reverse” vaccinology (Rappuoli, 2001; 810 
Mora et al., 2003).  Analyses of the genome and transcriptome sequence data of N. 811 
caninum may identify new vaccine candidates (possibly for insertion into a suitable 812 
delivery system, such as a potent vector); the currently available knowledge on parasitic 813 
vaccines would tend to suggest an approach that favours the identification of novel 814 
“hidden” or surface antigens for future evaluation 815 
A vaccine for dogs has also not been considered in detail.  The unclear role of 816 
canids in post-natal infection of cattle has delayed debate about whether a transmission-817 
blocking vaccine would be worthwhile for the farm setting.  Oocyst production by a 818 
definitive host may be targeted through vaccines that affect sexual stages (Wallach et al., 819 
1995, 2008) but there has been no progress in defining those in N. caninum.  However 820 
this remains a potentially fruitful area of research for the future. 821 
The future for the development of a vaccine that prevents abortion in cattle due to 822 
neosporosis is clearly bright, with many opportunities open for evaluation.  There are 823 
many leads to follow, and a bottleneck in the discovery process is the costs and time-824 
frame associated with conducting cattle trials. 825 
In summary, N. caninum infection and abortion in cattle is the cause of significant 826 
economic loss to the primary producer.  Economic analysis suggests huge up-side and 827 
potential for vaccine manufacturers, with efficacious vaccines having the potential to 828 




establish a clear need and market for an efficacious N. caninum vaccine and development 830 
efforts should rapidly follow in this area. 831 
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Figure legends 1403 
 1404 
Fig. 1. Mid-term aborted bovine foetus from a farm with chronic, sporadic Neospora 1405 
caninum abortions (from the study by Hall et al., 2005).  1406 
 1407 
Fig. 2. Example of a decision-tree analysis of the cost of Neospora caninum infection (do 1408 
nothing option/live with the infection equals NZD 97,154.79) in an average-sized dairy 1409 
herd in New Zealand versus the cost of various control options viewed over a 5 year 1410 
horizon (for further details see also Reichel and Ellis (2006)). A once-a-lifetime 1411 
vaccination with an attenuated (but highly efficacious) vaccine (utilising the NC-Nowra 1412 
Australian isolate) for N. caninum would cost the average N. caninum-infected herd just 1413 
NZD 8,248.74 over 5 years. 1414 
 1415 
Fig. 3. Brain lesions in a Neospora caninum-infected mouse. A) Perivascular cuffing; B) 1416 
necrosis; C) necrosis with mineralisation; D) meningitis. 1417 
 1418 
Fig. 4. Ruffled coat in a BALB/c mouse after experimental Neospora caninum infection. 1419 
 1420 
Fig. 5. Foetal death at implantation sites in the uterus due to Neospora caninum infection.  1421 
The arrows point to the dead/dying implantation sites which are discoloured. 1422 
 1423 
Fig. 6. A comparison of the Quackenbush (Qs) (left) and BALB/C mouse (right) showing 1424 





Table 1. Assessment of mouse morbidity (modified from Bartley et al., 2006). 1427 
 1428 
 1429 
Category Features Score 
A Sleek glossy coat 0 
Febrile response Ruffled coat 1 
 Stary stiff coat 2 
   
B   
Dehydration/loss of appetite Weight maintained at pre-infection level 0 
 10% weight loss 1 
 20% weight loss 2 
   
C Bright and active 0 
Demeanor Hunched appearance 1 
(accumulative scoring in C) Tottering gait 1 
 Reluctance to move 1 
 1430 





Table 2. Assessment of lesion scores in brain tissue of mice infected with a sub-lethal 1433 





0 No lesions present 
1 Minimal number of lesions present limited to lymphoplasmacellular 
meningitis and perivasculitis 
2 Mild lesions present including meningitis, perivasculitis and focal glial cell 
activation 
3 Moderate lesion including meningitis, perivasculitis, glial cell activation and 
rarefaction of the neuropil with macrophage infiltration 
4 Moderate lesion including meningitis, perivasculitis, glial cell activiation and 
rarefaction of the neuropil with macrophage infiltration, and focally extensive 
necrosis 
 1436 
Total number of lesions per sample/number of sections counted for that sample 1437 







Table 3. Efficacy of candidate vaccines/antigens in laboratory animals (cerebral 1442 
neosporosis model).  For standardization, the best estimates are presented for each study 1443 
after recalculation compared to the relevant controls presented. 1444 
 1445 
 1446 
Vaccine  Protection (% 
efficacy)a 
Protection criterion Animal 
Model 
Reference 





BALB/c (Bartley et al., 
2008) 
Lysate 64.7 Gerbil survival Gerbil (Cho et al., 2005) 
Irradiated tachyzoites 100; 0 Mouse survival; 
pathology 
C57BL/6 (Ramamoorthy et 
al., 2006) 
NcMIC1 40-100;18-100b; ns 
but lower or higher 
than controls 
Clinical signs; PCR; 
IHC 
C57BL/6 (Alaeddine et al., 
2005) 
RIBI adjuvant 50 Clinical signs C57BL/6 (Alaeddine et al., 
2005) 
NcMIC3 100;71;ns Clinical signs; PCR; 
IHC 
C57BL/6 (Cannas et al., 
2003b) 
NcMIC4 c (native) Significant reduction 
c 
PCR C57BL/6 (Srinivasan et al., 
2007) 
NcROP2 100;75 - 93 Clinical signs; PCR C57BL/6 (Debache et al., 
2008) 
cDNA + recSRS2 or 
recSAG1 
ns, ns, ns Mouse survival; 
PCR; IHC 
C57BL/6 (Cannas et al., 
2003a) 
MIC1, MIC3, GRA2, 
GRA6 and SRS2 in 
RB51 




C57BL/6 (Ramamoorthy et 
al., 2007b) 
RB51 control 69 Mouse survival C57BL/6 (Ramamoorthy et 
al., 2007b) 
RB51/SRS2 60-85e PCR BALB/c (Vemulapalli et 
al., 2007) 
NcSAG1, NcSRS2, 
NcDG1, or NcDG2 
30-61 Gerbil survival Gerbil (Cho et al., 2005) 
NcSRS2/vaccinia 33-42 PCR BALB/c (Nishikawa et al., 
2001a) 
NcSRS2 iscoms 0; reduction in 
parasite DNA present 
by 1.5 logs) 
Clinical signs; PCR BALB/c (Pinitkiatisakul et 
al., 2005) 
NcSRS2 iscoms 0;30-100 Clinical signs; PCR BALB/c (Pinitkiatisakul et 
al., 2007) 
a Estimated from a comparison of treatment and control groups; 1447 
b Data from adjuvant control confounds calculations; 1448 
c Injection causes increase in mouse mortality. Not possible to calculate protection from 1449 
data presented. 1450 




e Three mice (out of five) contained no parasite DNA (60% efficacy), and the other two 1452 
had very low amounts giving an overall level of protection significantly higher than 1453 




Table 4. Efficacy of candidate vaccines/antigens in laboratory animals (mouse vertical 1455 
transmission model).  For standardization, the best estimates are presented for each study 1456 
after recalculation compared to the relevant controls presented. 1457 
 1458 
 1459 







Live 89.5 PCR Qs (Miller et al., 
2005) 
Lysate 17.1-20.8 PCR Qs (Miller et al., 
2005) 
Lysate 100 PCR BALB/c (Liddell et al., 
1999b) 
MIC10 0 - 13.2 ns PCR Qs (Ellis et al., 2008) 
GRA1 14.9 ns PCR Qs (Ellis et al., 2008) 
GRA2 5.4 ns PCR Qs (Ellis et al., 2008) 
MIC 10 13.5 ns PCR Qs (Ellis et al., 2008) 
p24B 7.9 - 18.9 
ns 
PCR Qs (Ellis et al., 2008) 
MIC10 + p24B -2.7 ns - 
32.9 
PCR Qs (Ellis et al., 2008) 
MIC1, MIC3, GRA2, 






C57BL/6 (Ramamoorthy et 
al., 2007c) 
RB51 25/84.7 PCR/parasite 
burden 
C57BL/6 (Ramamoorthy et 
al., 2007c) 
GRA7, HSP33 47, 54 PCR BALB/c (Liddell et al., 
2003) 
GRA7 84.6 PCR BALB/c (Jenkins et al., 
2004a) 
NcSRS2/vaccinia 100/77.3 PCR/surviving 
pups 
BALB/c (Nishikawa et al., 
2001b) 
NcSRS2 61.3 PCR BALB/c (Haldorson et al., 
2005) 
 1460 
a Protection measured as a reduction in the transmission of the Neospora caninum 1461 
challenge compared to the control group. 1462 
b ns – observation not statistically significant 1463 















Live Cattle 100 Abortion (Williams et al., 
2007) 
Live Cattle 100 Transmission (Innes et al., 2001b) 




Sheep 85.7 Abortion (Jenkins et al., 
2004c) 
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